Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies

References

• Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in crohn’s disease. Am J Gastroenterol. 2008;103(4):944–948. doi: 10.1111/j.1572-0241.2007.01638.x.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in crohn’s disease. N Engl J Med. 2003;348(7):601–608. doi: 10.1056/NEJMoa020888.
   PubMed Web of Science ®Google Scholar
• Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (ibd): a meta-analysis. Am J Gastroenterol. 2013;108(1):40–47. doi: 10.1038/ajg.2012.363.
   PubMed Web of Science ®Google Scholar
• Sazonovs A, Kennedy NA, Moutsianas L, et al. Hla-dqa1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020;158(1):189–199. doi: 10.1053/j.gastro.2019.09.041.
   PubMed Web of Science ®Google Scholar
• Bots SJ, Parker CE, Brandse JF, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021;35(6):715–733. doi: 10.1007/s40259-021-00507-5.
   PubMed Web of Science ®Google Scholar
• Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63(8):1258–1264. doi: 10.1136/gutjnl-2013-305259.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-tnf treatment failure in anti-tnf-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353. doi: 10.1016/S2468-1253(19)30012-3.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–1468. doi: 10.1001/jama.2011.406.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711–715. doi: 10.1002/art.21671.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV, Jr., Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–1139. doi: 10.1038/ajg.2010.9.
   PubMed Web of Science ®Google Scholar
• Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522–530.e2. doi: 10.1016/j.cgh.2014.07.029.
   PubMed Web of Science ®Google Scholar
• Roblin X, Williet N, Boschetti G, et al. Addition of azathioprine to the switch of anti-tnf in patients with ibd in clinical relapse with undetectable anti-tnf trough levels and antidrug antibodies: a prospective randomised trial. Gut. 2020;69(7):1206–1212. doi: 10.1136/gutjnl-2019-319758.
   PubMed Web of Science ®Google Scholar
• Pariente B, Pineton de Chambrun G, Krzysiek R, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(7):1199–1206. doi: 10.1002/ibd.21839.
   PubMed Web of Science ®Google Scholar
• Strik AS, van den Brink GR, Ponsioen C, et al. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1128–1134. doi: 10.1111/apt.13994.
   PubMed Web of Science ®Google Scholar
• Husman J, Matthes K, Gilger M, et al. P787 subcutaneous infliximab in ibd patients with previous immunogenic failure of intravenous infliximab. J Crohn’s Colit. 2023;17(Supplement_1):i920–i920. doi: 10.1093/ecco-jcc/jjac190.0917.
   Google Scholar
• Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444–447. doi: 10.1016/j.cgh.2012.10.020.
   PubMed Web of Science ®Google Scholar
• Stallhofer J, Guse J, Kesselmeier M, et al. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-tnf therapy in inflammatory bowel disease. Int J Colorectal Dis. 2023;38(1):54. doi: 10.1007/s00384-023-04349-1.
   PubMed Web of Science ®Google Scholar
• Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45(2):276–282. doi: 10.1111/apt.13862.
   PubMed Web of Science ®Google Scholar
• Louis E, Resche-Rigon M, Laharie D, et al. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (spare): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(3):215–227. doi: 10.1016/S2468-1253(22)00385-5.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y, Ungar B, et al. Undetectable anti-tnf drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther. 2015;42(3):356–364. doi: 10.1111/apt.13268.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther. 2014;40(6):620–628. doi: 10.1111/apt.12869.
   PubMed Web of Science ®Google Scholar